Functional imaging by (18-F) fluorin-18-deoxyglucose positron emission tomography (FDG-PET) is an accurate modality to distinguish between viable tumor and necrosis or fibrosis in residual masses and is often used to evaluate therapy response in lymphoma. 1 However, the data on the utility of PET imaging in assessing disease response to salvage therapy in the setting of allogeneic hematopoietic cell transplantation (alloHCT) for nonHodgkin lymphoma (NHL) is limited. [2] [3] [4] We evaluated 73 patients with NHL treated between 2004 and 2010. Transplantation protocols and study design were approved by the Institutional Review Board, and informed consent was obtained prior to treatment. Patients underwent PET/computed tomography (CT) imaging less than 30 days before and at 100 days after allogeneic donor transplantation using the Siemens Biograph 16 PET scanner (Malvern, PA, USA). Imaging scans were centrally interpreted by one nuclear medicine radiologist (ATKK) according to standardized criteria using mediastinal/liver blood pool activity for comparison as defined by Deauvele criteria 1-5 (detailed in Figure 1 legend).
1 Follicular lymphoma was the most common lymphoma subset, followed by diffuse large B-cell lymphoma, T-cell lymphoma and mantle-cell lymphoma ( Table 1 ). The median age was 50 years and 60% were males. Most patients received reduced intensity conditioning, which consisted of fludarabine, CY and TBI as previously reported. 5 Myeloablative conditioning consisted of CY with fractionated TBI (1320 cGy). All patients received CYA from day 3 for a minimum of 100 days, followed by a taper through day 180. In addition, myeloablative conditioning patients received MTX 15 mg/m 2 i.v. on day +1 followed by 10 mg/ m 2 i.v. on days +3, +6 and +11. Mycophenolate mofetil (1-1.5 g i.v. or orally twice a day for the first 30 days) was used after reduced intensity conditioning and in all umbilical cord blood recipients after myeloablative conditioning. All patients received supportive care as previously reported. 5 Graft sources included umbilical cord blood (45%) or HLA-matched related donor (55%). Median followup was 3.3 years (range 1-6.7 years).
Pretransplantation PET performed at median of 17 days (range 4-39 days) prior to transplant detected lymphoma in 44 patients (Deauville score 4,5; PETpos 57% ) and 29 patients (43%) had no detectable lymphoma by PET (Deauville score 1-3; PETneg). Most PETpos patients (84%) were responders by CT criteria; 8% were in CR by CT, 23% had tumor size 43 cm (66% had 1-3 cm tumors), 16% had ⩾ 3 nodal sites involved by CT scan and 41% had extranodal disease (Table 1 ). Only four patients had lymphadenopathy ⩾ 5 cm and all were FDG-PET positive. Seven PETpos patients were chemorefractory and all had indolent histology. Two PETneg patients had low-level marrow involvement at the time of transplantation. Seven patients underwent prior autologous HCT. Other cohort characteristics were balanced in both PETpos and PETneg groups ( Table 1 ). The cumulative incidence of relapse/ progression at 2 years was 17% and was similar in patients who were PETpos and PETneg pre-transplantation (19% (95% confidence interval (CI) 7-31%) vs 15% (95% CI 1-28%); P = 0.48; Figure 1 ). Non-relapse mortality at 1 year was 11% (95% CI 4-18%) and was not affected by pre-transplant PET. In multivariariate analysis, a period of more than 2 years from diagnosis to transplantation was the only variable favorably associated with a lower relapse/progression rate (hazard ratio (HR) 0.28 (95% CI 0.08-1.0; P = 0.05) with no influence on PFS and OS. There was no difference in PFS according to age (450 years HR 0.87; 95% CI 0.28-2.64), gender (female HR 1.1; 95% CI 0.35-3.47), histology (diffuse large B-cell lymphoma HR 2.14; Mantle-cell HR 2.15 and T-cell NHL HR 1.68 compared with Follicular lymphoma, overall P = 0.73); reduced intensity conditioning (HR 1.75; 95% CI 0.45-5.75), donor type (umbilical cord blood HR 0.38; 95% CI 0.12-1.23), or marrow involvement at the time of transplant (HR 0.81; 95% CI 0.24-2.66). At 3 years, the PETpos group had similar PFS and OS compared with the PETneg group (PFS; 55% (95% CI 39-69) vs 62% (95% CI 38-79); P = 0.27; OS; 69% (95% CI 53-81%) vs 73% (95% CI 48-87); P = 0.39). PFS for follicular lymphoma was 72% (95% CI 46-87%) in PETpos and 60% (95% CI 20-85%) in PETneg patients (P = 0.69).
Post-transplant PET imaging was performed in 62 patients (85% of entire cohort) at day 100 and evaluated by Deauville score. 1 Of 44 patients with positive PET immediately pre-transplantation, half converted to PETneg remission with uptake less than mediastinal blood pool activity (n = 24, 52%). Notably, three out of four patients with large 45 cm PETpos lymphadenopathy attained PETneg remission at day 100. Patients with Deauville score 1-3 at100 days post transplant had 3-year PFS 73% (95% CI 58-86%) compared with 25% (95% CI 4-55%); P = 0.01) in patients with Deauville score 4-5. Abbreviations: CT = computed tomography; HCT = hematopoietic cell transplantation; PET = positron emission tomography. Letter to the Editor Consistent with recent reports from Memorial Sloan-Kettering Cancer Center and University College London, our study supports the conclusion that residual lymphoma as detected by fluorin-18-deoxyglucose PET imaging prior to allogeneic transplantation does not predict post-transplant relapse and survival. In our data set, positive PET avid activity pre-transplant does not preclude successful allotransplant. 2, 4 These findings are in contrast to highdose chemotherapy and autologous HCT, where FDG-PET adversely affects survival and have high predictive value. 6 We demonstrated that patients with FDG-avid viable lymphoma (mostly chemosensitive by conventional CT criteria) enjoyed favorable outcomes and a relatively low-relapse rate of 19%. In particular, we report excellent PFS in those patients who demonstrate no FDG-PET activity 100 days after allogeneic transplantation. The immunologically mediated graft-versuslymphoma effect [7] [8] [9] may eliminate the viable NHL in patients with FDG-PET positivity prior to transplant, remarkably even in some patients with larger tumor bulk indolent NHL. Limitations of this and other series include retrospective design, patient and transplant procedure heterogeneity, no detail on standardized uptake value and limited size of each lymphoma subset with potentially lower power of detecting differences in the primary end points within these groups [2] [3] [4] . Future investigations to refine the PET as a prognostic biomarker prior to alloHCT for NHL are needed. Prospective trials designed for specific lymphoma subsets should use standardized PET/CT procedures and Deauville criteria reporting, such as those recommended by Lugano International Conference on Malignant Lymphoma. 10 
